Trials
DUBLIN, IRELAND: Will Represent Sixth U.S. Patent to Be Listed in the Orange Book for RAVICTI
...
DUBLIN, IRELAND: Raises Full-Year 2016 Net Sales Guidance to $1.025 to $1.050 Billion; Raises Full-Year 2016 Adjusted EBITDA Guidance to $505 Million to $520 Million; Hart-Scott-Rodino Waiting Period Expired Effective ...
LYON, FRANCE: Reaffirmed Product Revenue Guidance for 2015 of $170-$185 Million; Licensed LiquiTime(R) to Perrigo for the U.S. OTC Market
...
COLUMBIA, MD and TORONTO, ON: Papers to Discuss Heat-Activated and Tumor Targeted Immunotherapy and Gene Therapy; Medifocus Inc.'s CEO Dr. Augustine Cheung Chairing Anticancer Targeted Drug Delivery Session
...
DUBLIN, IRELAND: Principal Purpose of the Meeting Is to Take Actions Relating to Horizon Pharma's Proposed Acquisition of Depomed, Inc.
...
WOBURN, MA: Will Exhibit at the World ADC 2015, Oct. 19-22 in San Diego, Booth #18
...
DUBLIN, IRELAND: Intends to Solicit Proxies From Depomed Inc. Shareholders for the Removal and Replacement of Depomed's Current Board and the Repeal of a Series of Recent Amendments to Depomed's Bylaws
...
DUBLIN, IRELAND: Phase 1 Trial of Potential Best-in-Class Neprilysin Inhibitor Planned for Q4 2015; Compound Designed for Broad Use in Major Cardiovascular and Renal Diseases
...
DUBLIN, IRELAND: Company Seeks Expanded Label Supporting VIBATIV Use Against Concurrent Bacteremia in Cases of Complicated Skin and Skin Structure Infections (cSSSI) or Hospital-Acquired and Ventilator-Associated Bact ...
